Close menu
  • News
  • Products
  • Contact
    • Send a Release
    • Sign Up
    • Log In
    • Resources
    • Blog
    • Journalists
    • RSS
    • GDPR
    • 3 News in Focus
    • 5 Business & Money
    • 5 Science & Tech
    • 5 Lifestyle & Health
    • 0 Policy & Public Interest
    • 1 People & Culture
    • Send a Release
    • Sign Up
    • Log In
    • Resources
    • Blog
    • Journalists
    • RSS
    • GDPR
    • Overview
    • Distribution by PR Newswire
    • Cision IR
    • SocialBoost
    • All Products
    • Send a Release
    • Sign Up
    • Log In
    • Resources
    • Blog
    • Journalists
    • RSS
    • GDPR
    • General Inquiries
    • Editorial Bureaus
    • Partnerships
    • Media Inquiries
    • Worldwide Offices
    • Send a Release
    • Sign Up
    • Log In
    • Resources
    • Blog
    • Journalists
    • RSS
    • GDPR
    Close submenu (News in Focus)News in Focus
    • Browse All News
    • Multimedia Gallery
    • Trending Topics
    Close submenu (Business & Money)Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
    Close submenu (Science & Tech)Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
    Close submenu (Lifestyle & Health)Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
    Close submenu (Policy & Public Interest)Policy & Public Interest
    Close submenu (People & Culture)People & Culture
    • People & Culture
    Accessibility Statement Skip Navigation
    • Resources
    • Blog
    • Journalists
    • Log In
    • Sign Up
    • Data Privacy
    • Send a Release
    Return to PR Newswire homepage
    • News
    • Products
    • Contact
    When typing in this field, a list of search results will appear and be automatically updated as you type.

    Searching for your content...

    No results found. Please change your search terms and try again.
    • News in Focus
        • Browse News Releases

        • All News Releases
        • All Public Company
        • English-only
        • News Releases Overview

        • Multimedia Gallery

        • All Multimedia
        • All Photos
        • All Videos
        • Multimedia Gallery Overview

        • Trending Topics

        • All Trending Topics
    • Business & Money
        • Auto & Transportation

        • All Automotive & Transportation
        • Aerospace, Defense
        • Air Freight
        • Airlines & Aviation
        • Automotive
        • Maritime & Shipbuilding
        • Railroads and Intermodal Transportation
        • Supply Chain/Logistics
        • Transportation, Trucking & Railroad
        • Travel
        • Trucking and Road Transportation
        • Auto & Transportation Overview

        • View All Auto & Transportation

        • Business Technology

        • All Business Technology
        • Blockchain
        • Broadcast Tech
        • Computer & Electronics
        • Computer Hardware
        • Computer Software
        • Data Analytics
        • Electronic Commerce
        • Electronic Components
        • Electronic Design Automation
        • Financial Technology
        • High Tech Security
        • Internet Technology
        • Nanotechnology
        • Networks
        • Peripherals
        • Semiconductors
        • Business Technology Overview

        • View All Business Technology

        • Entertain­ment & Media

        • All Entertain­ment & Media
        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertain­ment & Media Overview

        • View All Entertain­ment & Media

        • Financial Services & Investing

        • All Financial Services & Investing
        • Accounting News & Issues
        • Acquisitions, Mergers and Takeovers
        • Banking & Financial Services
        • Bankruptcy
        • Bond & Stock Ratings
        • Conference Call Announcements
        • Contracts
        • Cryptocurrency
        • Dividends
        • Earnings
        • Earnings Forecasts & Projections
        • Financing Agreements
        • Insurance
        • Investments Opinions
        • Joint Ventures
        • Mutual Funds
        • Private Placement
        • Real Estate
        • Restructuring & Recapitalization
        • Sales Reports
        • Shareholder Activism
        • Shareholder Meetings
        • Stock Offering
        • Stock Split
        • Venture Capital
        • Financial Services & Investing Overview

        • View All Financial Services & Investing

        • General Business

        • All General Business
        • Awards
        • Commercial Real Estate
        • Corporate Expansion
        • Earnings
        • Environmental, Social and Governance (ESG)
        • Human Resource & Workforce Management
        • Licensing
        • New Products & Services
        • Obituaries
        • Outsourcing Businesses
        • Overseas Real Estate (non-US)
        • Personnel Announcements
        • Real Estate Transactions
        • Residential Real Estate
        • Small Business Services
        • Socially Responsible Investing
        • Surveys, Polls and Research
        • Trade Show News
        • General Business Overview

        • View All General Business

    • Science & Tech
        • Consumer Technology

        • All Consumer Technology
        • Artificial Intelligence
        • Blockchain
        • Cloud Computing/Internet of Things
        • Computer Electronics
        • Computer Hardware
        • Computer Software
        • Consumer Electronics
        • Cryptocurrency
        • Data Analytics
        • Electronic Commerce
        • Electronic Gaming
        • Financial Technology
        • Mobile Entertainment
        • Multimedia & Internet
        • Peripherals
        • Social Media
        • STEM (Science, Tech, Engineering, Math)
        • Supply Chain/Logistics
        • Wireless Communications
        • Consumer Technology Overview

        • View All Consumer Technology

        • Energy & Natural Resources

        • All Energy
        • Alternative Energies
        • Chemical
        • Electrical Utilities
        • Gas
        • General Manufacturing
        • Mining
        • Mining & Metals
        • Oil & Energy
        • Oil and Gas Discoveries
        • Utilities
        • Water Utilities
        • Energy & Natural Resources Overview

        • View All Energy & Natural Resources

        • Environ­ment

        • All Environ­ment
        • Conservation & Recycling
        • Environmental Issues
        • Environmental Policy
        • Environmental Products & Services
        • Green Technology
        • Natural Disasters
        • Environ­ment Overview

        • View All Environ­ment

        • Heavy Industry & Manufacturing

        • All Heavy Industry & Manufacturing
        • Aerospace & Defense
        • Agriculture
        • Chemical
        • Construction & Building
        • General Manufacturing
        • HVAC (Heating, Ventilation and Air-Conditioning)
        • Machinery
        • Machine Tools, Metalworking and Metallurgy
        • Mining
        • Mining & Metals
        • Paper, Forest Products & Containers
        • Precious Metals
        • Textiles
        • Tobacco
        • Heavy Industry & Manufacturing Overview

        • View All Heavy Industry & Manufacturing

        • Telecomm­unications

        • All Telecomm­unications
        • Carriers and Services
        • Mobile Entertainment
        • Networks
        • Peripherals
        • Telecommunications Equipment
        • Telecommunications Industry
        • VoIP (Voice over Internet Protocol)
        • Wireless Communications
        • Telecomm­unications Overview

        • View All Telecomm­unications

    • Lifestyle & Health
        • Consumer Products & Retail

        • All Consumer Products & Retail
        • Animals & Pets
        • Beers, Wines and Spirits
        • Beverages
        • Bridal Services
        • Cannabis
        • Cosmetics and Personal Care
        • Fashion
        • Food & Beverages
        • Furniture and Furnishings
        • Home Improvement
        • Household, Consumer & Cosmetics
        • Household Products
        • Jewelry
        • Non-Alcoholic Beverages
        • Office Products
        • Organic Food
        • Product Recalls
        • Restaurants
        • Retail
        • Supermarkets
        • Toys
        • Consumer Products & Retail Overview

        • View All Consumer Products & Retail

        • Entertain­ment & Media

        • All Entertain­ment & Media
        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertain­ment & Media Overview

        • View All Entertain­ment & Media

        • Health

        • All Health
        • Biometrics
        • Biotechnology
        • Clinical Trials & Medical Discoveries
        • Dentistry
        • FDA Approval
        • Fitness/Wellness
        • Health Care & Hospitals
        • Health Insurance
        • Infection Control
        • International Medical Approval
        • Medical Equipment
        • Medical Pharmaceuticals
        • Mental Health
        • Pharmaceuticals
        • Supplementary Medicine
        • Health Overview

        • View All Health

        • Sports

        • All Sports
        • General Sports
        • Outdoors, Camping & Hiking
        • Sporting Events
        • Sports Equipment & Accessories
        • Sports Overview

        • View All Sports

        • Travel

        • All Travel
        • Amusement Parks and Tourist Attractions
        • Gambling & Casinos
        • Hotels and Resorts
        • Leisure & Tourism
        • Outdoors, Camping & Hiking
        • Passenger Aviation
        • Travel Industry
        • Travel Overview

        • View All Travel

    • Policy & Public Interest
        • Policy & Public Interest

        • All Policy & Public Interest
        • Advocacy Group Opinion
        • Animal Welfare
        • Congressional & Presidential Campaigns
        • Corporate Social Responsibility
        • Domestic Policy
        • Economic News, Trends, Analysis
        • Education
        • Environmental
        • European Government
        • FDA Approval
        • Federal and State Legislation
        • Federal Executive Branch & Agency
        • Foreign Policy & International Affairs
        • Homeland Security
        • Labor & Union
        • Legal Issues
        • Natural Disasters
        • Not For Profit
        • Patent Law
        • Public Safety
        • Trade Policy
        • U.S. State Policy
        • Policy & Public Interest Overview

        • View All Policy & Public Interest

    • People & Culture
        • People & Culture

        • All People & Culture
        • Aboriginal, First Nations & Native American
        • African American
        • Asian American
        • Children
        • Diversity, Equity & Inclusion
        • Hispanic
        • Lesbian, Gay & Bisexual
        • Men's Interest
        • People with Disabilities
        • Religion
        • Senior Citizens
        • Veterans
        • Women
        • People & Culture Overview

        • View All People & Culture

        • In-Language News

        • Arabic
        • español
        • português
        • Česko
        • Danmark
        • Deutschland
        • España
        • France
        • Italia
        • Nederland
        • Norge
        • Polska
        • Portugal
        • Россия
        • Slovensko
        • Suomi
        • Sverige
    • Overview
    • Distribution by PR Newswire
    • Cision IR
    • Guaranteed Paid Placement
    • SocialBoost
    • All Products
    • General Inquiries
    • Editorial Bureaus
    • Partnerships
    • Media Inquiries
    • Worldwide Offices
    • Hamburger menu
    • PR Newswire: news distribution, targeting and monitoring
    • Send a Release
      • ALL CONTACT INFO
      • Contact Us

        888-776-0942
        from 8 AM - 10 PM ET

    New Late Breaking Data Show Patients Treated with Penumbra's Computer Assisted Vacuum Thrombectomy Technology for Pulmonary Embolism Experience Shorter Hospital Stays and Fewer Complications Compared to Other Treatment Options

    Penumbra, Inc. Logo (PRNewsFoto/Penumbra, Inc.)

    News provided by

    Penumbra, Inc.

    Nov 05, 2024, 09:00 ET

    Share this article

    Share toX

    Share this article

    Share toX

    • Data presented for the first time this week at Vascular Interventional Advances (VIVA) 2024 Conference
    • Findings reinforce the clinical, health economic and cost benefits of computer assisted vacuum thrombectomy to patients and the overall health system

    ALAMEDA, Calif., Nov. 5, 2024 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN), the world's leading thrombectomy company, announced new data that demonstrate patients with intermediate-risk pulmonary embolism (PE) treated with Penumbra's computer assisted vacuum thrombectomy (CAVT™) technology have a shorter length of hospital stay, shorter post-procedure length of stay and fewer complications when compared to other treatment options. Additionally, in-hospital mortality was low with CAVT, with no significant difference between treatment options. The late-breaking study was presented this week at the Vascular Interventional Advances (VIVA) 2024 Conference.

    "This first-of-a-kind analysis demonstrates that patients treated with CAVT utilized fewer hospital resources," said Parag J. Patel, M.D., M.S., FSIR, who presented the data and is an interventional radiologist at Froedtert Hospital in Milwaukee, WI. "These findings, as well as recent studies which show CAVT's positive impact on patient outcomes, strongly showcase the significant benefits of CAVT over other treatment options for PE. We will continue to see the growing adoption of CAVT as a frontline therapy given the notable beneficial impact on patients and the overall health system."

    The retrospective study utilized the Vizient Clinical Data Base to identify 2,060 adult (³18 years) inpatients with intermediate-risk PE. This rigorous 1:1 propensity score matched analysis included resource use and health outcomes among patients in the U.S. treated with Penumbra's Lightning™ Flash™ or Lightning 12 technology compared to patients in the U.S. treated with anticoagulation, catheter directed thrombolysis or other mechanical thrombectomy devices.

    When compared to other modalities studied, the data showed that CAVT resulted in:

    • 25-35 percent shorter total hospital length of stay
    • 25-30 percent higher average rate of patients discharged home
    • 2-3 times fewer average composite complications

    "CAVT will continue to redefine the way physicians treat symptomatic PE. We have a growing body of evidence that demonstrates the meaningful benefits of CAVT on patient outcomes," said James F. Benenati, M.D., FSIR, chief medical officer at Penumbra. "Now with this study, the findings suggest that by increasing patient access to advanced therapies like CAVT, it can also have an important, positive impact on hospital systems by greatly reducing resource utilization versus other modalities, therefore decreasing the overall cost to the healthcare system."

    In the study, CAVT was associated with improvement in contribution margin relative to anticoagulation alone. An example given was that if 10 percent more patients are treated with CAVT, hospitals could see up to a 75 percent gain in profitable contribution margin, representing thousands of dollars more per patient compared to treatment with anticoagulation alone. This data was presented separately in a symposium during the VIVA 2024 Conference.

    Penumbra's Lightning Flash portfolio is the most advanced mechanical thrombectomy system on the market to address venous and pulmonary thrombus. It features Penumbra's Lightning CAVT technology with the latest dual clot detection algorithms, using both pressure and flow-based processes to detect blood clot and blood flow. The Lightning Flash™ and Lightning Flash™ 2.0 catheters are made with MaxID hypotube technology, allowing an inner diameter similar to large-bore catheters while maintaining a lower profile and a soft, atraumatic tip design. They are designed to help remove blood clots with speed, safety and simplicity, allowing physicians to better navigate the body's complex anatomy and deliver high power aspiration for clot removal.

    About Penumbra
    Penumbra, Inc., the world's leading thrombectomy company, is focused on developing the most innovative technologies for challenging medical conditions such as ischemic stroke, venous thromboembolism such as pulmonary embolism, and acute limb ischemia. Our broad portfolio, which includes computer assisted vacuum thrombectomy (CAVT), centers on removing blood clots from head-to-toe with speed, safety and simplicity. By pioneering these innovations, we support healthcare providers, hospitals and clinics in more than 100 countries, working to improve patient outcomes and quality of life. For more information, visit www.penumbrainc.com and connect on Instagram, LinkedIn and X.

    Important Safety Information
    Additional information about Penumbra's products can be located on Penumbra's website at https://www.penumbrainc.com/providers. Prior to use, please refer to Instructions for Use for complete product indications, contraindications, warnings, precautions, potential adverse events and detailed instructions for use. Risk information can be found at http://www.peninc.info/risk.

    Forward-Looking Statements
    Except for historical information, certain statements in this press release are forward-looking in nature and are subject to risks, uncertainties and assumptions about us. Our business and operations are subject to a variety of risks and uncertainties and, consequently, actual results may differ materially from those projected by any forward-looking statements. Factors that could cause actual results to differ from those projected include, but are not limited to: failure to sustain or grow profitability or generate positive cash flows; failure to effectively introduce and market new products; delays in product introductions; significant competition; inability to further penetrate our current customer base, expand our user base and increase the frequency of use of our products by our customers; inability to achieve or maintain satisfactory pricing and margins; manufacturing difficulties; permanent write-downs or write-offs of our inventory or other assets; product defects or failures; unfavorable outcomes in clinical trials; inability to maintain our culture as we grow; fluctuations in foreign currency exchange rates; potential adverse regulatory actions; and the potential impact of any acquisitions, mergers, dispositions, joint ventures or investments we may make. These risks and uncertainties, as well as others, are discussed in greater detail in our filings with the Securities and Exchange Commission (SEC), including our Annual Report on Form 10-K for the year ended December 31, 2023 filed with the SEC on February 22, 2024. There may be additional risks of which we are not presently aware or that we currently believe are immaterial which could have an adverse impact on our business. Any forward-looking statements are based on our current expectations, estimates and assumptions regarding future events and are applicable only as of the dates of such statements. We make no commitment to revise or update any forward-looking statements in order to reflect events or circumstances that may change.

    Contact



    Jennifer Heth


    Parinaz Farzin 

    Penumbra, Inc.


    Merryman Communications

    jheth@penumbrainc.com


    parinaz@merrymancommunications.com

    510-995-9791


    310.600.6746

    SOURCE Penumbra, Inc.

    WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

    icon3
    440k+
    Newsrooms &
    Influencers
    icon1
    9k+
    Digital Media
    Outlets
    icon2
    270k+
    Journalists
    Opted In
    GET STARTED

    Modal title

    Also from this source

    Penumbra, Inc. to Present at the 43rd Annual J.P. Morgan Healthcare Conference

    Penumbra, Inc. to Present at the 43rd Annual J.P. Morgan Healthcare Conference

    Penumbra, Inc. (NYSE: PEN) today announced that its management team is scheduled to present at the 43rd Annual J.P. Morgan Healthcare Conference on...

    Penumbra, Inc. to Present at the Piper Sandler 36th Annual Healthcare Conference

    Penumbra, Inc. to Present at the Piper Sandler 36th Annual Healthcare Conference

    Penumbra, Inc. (NYSE: PEN) today announced that its management team is scheduled to present at the Piper Sandler 36th Annual Healthcare Conference on ...

    More Releases From This Source

    Explore

    Health Care & Hospitals

    Health Care & Hospitals

    Medical Pharmaceuticals

    Medical Pharmaceuticals

    Clinical Trials & Medical Discoveries

    Clinical Trials & Medical Discoveries

    Trade Show News

    Trade Show News

    News Releases in Similar Topics

    Contact PR Newswire

    • Call PR Newswire at 888-776-0942
      from 8 AM - 9 PM ET
    • Chat with an Expert
    • General Inquiries
    • Editorial Bureaus
    • Partnerships
    • Media Inquiries
    • Worldwide Offices

    Products

    • For Marketers
    • For Public Relations
    • For IR & Compliance
    • For Agency
    • For Small Business
    • All Products

    About

    • About PR Newswire
    • About Cision
    • Become a Publishing Partner
    • Become a Channel Partner
    • Careers
    • Accessibility Statement
    • Asia
    • APAC
    • APAC - Traditional Chinese
    • Brazil
    • Canada
    • Czech
    • Denmark
    • Finland
    • France
    • Germany
    • India
    • Indonesia
    • Israel
    • Korea
    • Italy
    • Japan
    • Mexico
    • Middle East
    • Middle East - Arabic
    • Netherlands
    • Norway
    • Poland
    • Portugal
    • Russia
    • Slovakia
    • Spain
    • Sweden
    • United Kingdom

    My Services

    • All New Releases
    • Online Member Center
    • ProfNet

    Do not sell or share my personal information:

    • Submit via Privacy@cision.com 
    • Call Privacy toll-free: 877-297-8921

    Contact PR Newswire

    Products

    About

    My Services
    • All News Releases
    • Online Member Center
    • ProfNet
    Call PR Newswire at
    888-776-0942
    • Terms of Use
    • Privacy Policy
    • Information Security Policy
    • Site Map
    • RSS
    • Cookie Settings
    Copyright © 2025 Cision US Inc.